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The interaction of amyloid-beta (Ab) and tau in the pathogenesis of Alzheimer’s disease is a subject of
intense inquiry, with the bulk of evidence indicating that changes in tau are downstream of Ab. It has
been shown however, that human tau overexpression in amyloid precursor protein transgenic mice
increases Ab plaque deposition. Here, we conﬁrm that human tau increases Ab levels. To determine if the
observed changes in Ab levels were because of intracellular or extracellular secreted tau (eTau for
extracellular tau), we afﬁnity puriﬁed secreted tau from Alzheimer’s disease patientederived cortical
neuron conditioned media and analyzed it by liquid chromatography-mass spectrometry. We found the
extracellular species to be composed predominantly of a series of N-terminal fragments of tau, with no
evidence of C-terminal tau fragments. We characterized a subset of high afﬁnity tau antibodies, each
capable of engaging and neutralizing eTau. We found that neutralizing eTau reduces Ab levels in vitro in
primary human cortical neurons where exogenously adding eTau increases Ab levels. In vivo, neutralizing
human tau in 2 human tau transgenic models also reduced Ab levels. We show that the human tau insert
sequence is sufﬁcient to cause the observed increase in Ab levels. Our data furthermore suggest that
neuronal hyperactivity may be the mechanism by which this regulation occurs. We show that neuronal
hyperactivity regulates both eTau secretion and Ab production. Electrophysiological analysis shows for
the ﬁrst time that secreted eTau causes neuronal hyperactivity. Its induction of hyperactivity may be the
mechanism by which eTau regulates Ab production. Together with previous ﬁndings, these data posit a
novel connection between tau and Ab, suggesting a dynamic mechanism of positive feed forward
regulation. Ab drives the disease pathway through tau, with eTau further increasing Ab levels, perpet-
uating a destructive cycle.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is characterized pathologically by
amyloid-beta (Ab) plaques and tau dominated neuroﬁbrillary tan-
gles (NFTs). Understandably, the ﬁeld has focused on elucidating
the mechanisms regulating these hallmark AD proteins and inves-
tigating their interplay in disease. Ab is formed by the sequential
cleavage of amyloid precursor protein (APP) by b- and g-secretase.
The accumulation of Ab peptide in extracellular plaques is tradi-
tionally seen as the primary event in AD, with subsequent NFT
formation and neuronal and synaptic loss following as a directBY-NC-ND license (http://
ay Blvd, SSF CA 94080, USA.
cy Stagliano).
Published by Elsevier Inc. All righresult; collectively known as the amyloid cascade hypothesis
(Hardy and Higgins, 1992; Hardy and Selkoe, 2002).
Work performed with frontotemporal dementia mutant tau
(P301L) transgenic mice injected with aggregated Ab (Gotz et al.,
2001) as well as experiments using APP and tau bigenic mice
(Lewis et al., 2001) indicates an upstream role for Ab oligomeriza-
tion in initiating tau pathology. In vitro and in vivo models show Ab
induced neurotoxicity and Ab induced axonal transport deﬁcits are
ameliorated by dose-dependent reductions in tau (Rapoport et al.,
2002; Vossel et al., 2010). In hippocampal slice preparations, Ab-
induced impairment of long-term potentiation is inhibited in slices
generated from tau/ mice (Shipton et al., 2011). In the J20 APP
transgenic mouse, reducing endogenous mouse tau decreased or
eliminated learning and memory deﬁcits, exploratory loco motor
hyperactivity, interictal spiking, spontaneous seizures, and early
mortality (Roberson et al., 2007, 2011). In the APP23 transgenic
mice, reducing tau dose dependently improved memory in thets reserved.
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2010). The exact downstreammechanism involved in taumediating
protection from Ab toxicity has yet to be shown. Elimination of
mouse tau in these APP transgenic animals mitigates disease phe-
notypes but does not alter Ab levels or plaque burden (Ittner et al.,
2010; Roberson et al., 2007).
In contrast to these ﬁndings, work done with double transgenic
mice expressing both human mutant tau and APP showed greater
Ab deposition and NFT-like formation with increased neuronal loss
in double transgenic animals when compared with single trans-
genic controls (Ribe et al., 2005). Furthermore, Braak and Braak
(1995) have shown with their analysis of brain slices taken from
patient autopsy samples still in the presymptomatic stages of AD,
Braak-stage I-III, that intraneuronal tau alterations precede aggre-
gated Ab deposition (Braak and Del, 2004; Braak et al., 2013;
Schonheit et al., 2004). They present evidence that tau tangles
temporally develop either before or independent of Ab plaques.
These divergent ﬁndings indicate that the causal link between
aberrant APP processing and tau alterations remains controversial.
Recent AD research places tau in the extracellular space under
physiological conditions (Yamada et al., 2011) and shows endoge-
nous tau to be actively secreted from human (Chai et al., 2012) and
rat neurons (Pooler et al., 2013). In concert with these observations,
others have found that tau pathology spreads in AD. Early in dis-
ease, tau tangles are detectable in the entorhinal cortex and as the
disease progresses tau pathology spreads into the hippocampus
and cortex (Braak and Braak, 1995).
The spread of tau tangle pathology occurs concomitantly with
clinical disease progression, moving frommemory loss to dementia.
In in vivo models in which human tau is speciﬁcally overexpressed
in the entorhinal cortex, tau is secreted and spreads along synaptic
circuitry, resulting in tau pathology progression from the entorhinal
cortex, through the hippocampus, and into the cortex (de Calignon
et al., 2012; Dujardin et al., 2014; Liu et al., 2012). Furthermore,
comparative analysis of AD and healthy patient cerebral spinal ﬂuid
(CSF) showed a clear increase of amino-terminal (N-terminal) tau
fragments in AD patient CSF, with no evidence of full-length or
carboxyl-terminal (C-terminal) tau (Meredith et al., 2013). This is in
contrast to data suggesting that tau in the interstitial ﬂuid (ISF) of
P301L mice is of full length (Yamada et al., 2011).
Presynaptic release of secreted tau from cortical neurons has
been shown to be mediated by neuronal activity. Yamada et al.
(2014) used in vivo microdialysis in mouse brain to show that
increasing neuronal and synaptic activity rapidly increases steady-
state levels of transgenic extracellular tau. Additionally, in vitro
treatment of rat neurons with the sodium channel blocker tetro-
dotoxin (TTX) prevents AMPA-mediated tau release (Pooler et al.,
2013).Table 1
Patient information induced pluripotent stem cell derived cortical neurons (iPSC-CN)
Patient status Mutation Number of
iPSC-CN lines tested/patient
iPSC lin
fAD PSEN1
A260V
3 fAD1.1
fAD1.2
fAD1.3
fAD PSEN1
L286V
1 fAD1.1
fAD PSEN1
L418F
2 fAD1.1
fAD1.2
fAD PSEN2
N141I
3 fAD2.1
fAD2.2
fAD2.3
sAD Unknown 1 sAD1.1
Key: apoE, apolipoprotein E; eTau, extracellular tau; fAD, familial AD; iPSC-CN, iPSC deri
Y, yes.In fact both tau and Ab have been shown to be affected by
neuronal hyperactivity. Cirrito et al. (2005), (2008); DeVos et al.
(2013); Kamenetz et al. (2003); and Verges et al. (2011) have
demonstrated in vitro and in vivo that soluble Ab levels in brain are
directly inﬂuenced by neuronal, and more speciﬁcally, synaptic
activity. They postulated a negative feedback role for Ab in healthy
neurons, functioning to keep neuronal hyperactivity in check by
selectively depressing excitatory synaptic transmission. Taken
together, these ﬁndings indicate a direct correlation between re-
ductions in tau protein with reductions in neuronal hyperactivity,
both of which correspond to a decrease in soluble Ab levels.
Here, we have identiﬁed the major forms of human tau
secreted from AD patientederived cortical neurons to be a pool of
secreted N-terminal tau fragments which we call eTau, for extra-
cellular tau. We show that eTau, and more speciﬁcally the human
tau insert region, increases soluble Ab levels while simultaneously
lowering the neuroprotective product of a-secretase APP cleavage,
soluble amyloid precursor protein-a (sAPPa), suggesting that eTau
modulates Ab production. We show this eTau/Ab relationship in
both primary human in vitro neuronal cultures and in vivo tau
transgenic models. Additionally, we observed that eTau induces
neuronal hyperactivity when applied to cortical cultures and
found that reducing or neutralizing eTau prevents aberrant
neuronal hyperactivity. We suggest that eTau induced hyperac-
tivity is negatively impacting neurons, and that eTau may elevate
Ab production in AD brain.
2. Methods
2.1. Primary human cortical neuron cultures
Human cortical neuron cultures were prepared as described
(Wright et al., 2012) and cultured for 3 weeks in Neurobasal me-
dium with B27 and Glutamax (Invitrogen) before the start of 20
days treatments. Human fetal cerebral cortical tissue was obtained
by Advanced Bioscience Resources (Alameda, CA, USA) and com-
plied with federal guidelines for fetal research and with the Uni-
formed Anatomical Gift Act.
2.2. Induced pluripotent stem cells patient-derived cortical neurons
Induced pluripotent stem cells (iPSC) were generated using the
Yamanaka method (Takahashi et al., 2007) as previously described
(Dimos et al., 2008) from skin biopsies taken from a familial
presenilin-1 (A260V) AD patient aged 50 years and a sporadic AD
patient aged 60 years. Brieﬂy, iPSC were differentiated to neurons
via dual SMAD (small body size mothers against decapentaplegic)
inhibition (Chambers et al., 2009) followed by cortical neurone name ApoE genotype Age at biopsy Used for
eTau puriﬁcation
E3/E3 50 Y
E3/E3 38 N
E3/E4 39 N
E3/E3 81 N
E4/E4 60 Y
ved cortical neurons; iPSC, induced pluripotent stem cells; N, no; sAD, sporadic AD;
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cortical neurons (iPSC-CN) were grown between 70 and
108 days with media changes every 3 days unless otherwise noted.
A list of AD patient samples used to generate individual iPSC
clones, as well as their relevant mutations, is provided in Table 1.
2.3. Antibodies
2.3.1. iPierian tau antibodies
Tau sizes are represented based on 2N4R tau sequence length
unless otherwise noted.
IPN001 and IPN002 (iPierian) are mouse monoclonal antibodies
generated by standard immunizationwith in vitro aggregated 2N4R
tau, followed by clonal selection and antibody puriﬁcation from
hybridoma. Both antibodies were selected for their high binding
afﬁnity to both secreted eTau as well as full length tau (recombinant
Tau383, 0N4R form) and for their ability to neutralize secreted
eTau’s electrophysiological activity. They both bind to the N-ter-
minus of tau with epitopes spanning amino acids 15e24.
2.3.2. Antibodies
MC1 (Peter Davies) is a conformational monoclonal antibody
speciﬁc for a conformation change in tau found in AD brain, and
paired helical fragment 1 (PHF1) (Peter Davies) detects the pSer396/
404 tau epitope present on both normal adult brain tau and PHF tau
(Jicha et al.,1997). Commercialmousemonoclonal antibodies against
tau used are HT7 (aa 159e163, ThermoScientiﬁc), BT2 (aa 194e198,
ThermoScientiﬁc), and T46 (C-terminal tau near amino acids
404e441, Invitrogen). Rabbit polyclonal antibodies used were
against tau (aa 243e441, Dako) and against APP (C-terminal amino
acids, Sigma). Mouse monoclonal control antibodies used were to
b-actin (Abcam), a-tubulin (Cell Signaling), mouse IgG (R&D Sys-
tems), and mouse IgG whole molecule (Jackson).
2.4. Secreted tau characterization, puriﬁcation, and liquid
chromatography-mass spectrometry analysis
2.4.1. Secreted tau immunoprecipitation
iPSC-CN derived from a familial presenilin-1 (A260V) AD patient
aged 50 years were differentiated for 70 days at which point media
conditioned for 3 days was collected for tau immunoprecipitation.
Conditioned media was centrifuged at 15,000 rpm (4 C) and su-
pernatants precleared on a mouse IgG (Jackson) Sepharose 4B resin
(GE Healthcare) before immunoprecipitation on either an N-ter-
minal tau antibody, IPN002, a mid-region tau antibody, HT7, or a C-
terminal tau antibody, T46, each previously coupled to Sepharose
4B resins. After immunoprecipitation, all 3 bead sets werewashed 3
times with mammalian protein extraction buffer (M-PER, Ther-
moScientiﬁc) and immunoprecipitated protein extracted from
pelleted beads with 2X Laemmli reducing buffer (Sigma) and
separated on NuPage Bis-Tris protein gels (Invitrogen). Western
blots were probed for tau with IPN001 (1 mg/mL), analysis by
Odyssey SA software version 1.1.7 (LiCor). To ensure the tau speci-
ﬁcity of all 3 immunoprecipitations, iPSC-CN growth media was
incubatedwith the 3 antibody conjugated resins in parallel with the
conditioned media, and the resultant nonspeciﬁc eluate ran as
Media control on the IPN001 Western blot.
2.4.2. Secreted tau afﬁnity isolation
iPSC-CN generated from skin biopsies taken from a familial
presenilin-1 (A260V) AD patient aged 50 years and a sporadic AD pa-
tient aged 60 years were cultured for 108 days in total, with media
changesevery3days.Startingatday70of iPSC-CNculture, conditioned
media was collected every 3 days and pooled for secreted tau afﬁnity
isolation. Pooled conditioned media was centrifuged at 15,000 rpm(4 C) and supernatants precleared on amouse IgG Sepharose 4B resin
before tau puriﬁcation on N-terminal IPN002 anti-tau antibody
Sepharose 4B coupled resin. Protein was eluted with 50 mM sodium
citrate, pH 2.3, 150 mM NaCl, and neutralized with 1 M tris-buffered
saline (TBS), pH 8.3. The eluate was concentrated, and buffer
exchanged into phosphate-buffered saline (PBS) and here referenced
as eTau. Amock protein control was generated from a second batch of
pooled conditioned media, also precleared over the mouse IgG resin
before mock afﬁnity puriﬁcation using mouse IgG resin.
2.4.3. Liquid chromatography-mass spectrometry analysis
Side-by-side lanes of IPN002 afﬁnity puriﬁed eTau were sepa-
rated on reducing and/or denaturing 10% NuPage gel (Invitrogen),
and analyzed by Coomassie stain (LiCor) or transferred to nitro-
cellulose for Western blot analysis with iBlot (Life Technologies)
and probed for tau with IPN001 (1 mg/mL). Four Coomassie stained
and/or anti-tau conﬁrmed bands were excised from the gel and
submitted for LC/MS analysis (MS Bioworks). Protein was proteo-
lytically digested out of the gel slices with trypsin, chymotrypsin, or
elastase, and gel digests were analyzed by nano LC/MS with a
Waters NanoAcquity HPLC system interfaced to a ThermoFisher
Orbitrap Velos Pro. Data were searched using Mascot. This analysis
was veriﬁed using intact protein LC/MS analysis to ensure we
identiﬁed the ends of the tau fragments. Liquid chromatography
was performed on a C8 column (Agilent), and mass spec analysis
was performed on a Q-ToF Premiere (Waters).
2.5. eTau secretion Brefeldin treatment
Familial AD PSEN1 (A260V) iPSC-CN were cultured for
70e108 days then washed once with growth media before addition
of fresh growth media with and without 10 mg/mL Brefeldin A
(Sigma); media was conditioned for 4 hours at 37 C/5%CO2 and
collected for analysis by IPN001 (1 mg/mL)Western blot. Lysates from
treated wells were also harvested with 50 mL M-PER and b-actin
levels in the lysates were measured by Western blot for normaliza-
tion of eTau data.
2.6. Primary human cortical neuron treatments
Primaryhumancortical neuronswere treatedwith either 100nM
BACE1 inhibitor (BACEi) (Axon Medchem), tetrodotoxin (Tocris),
1 mM Accell siRNA pools against human MAPT, BACE1, ADAM9,
ADAM10, ADAM17, or nontargeting control (Thermo Scientiﬁc/
Dharmacon, catalog E-012488, E-003747, E-004504, E-004503, and
E-003453, respectively), 50 nM or 500 nM puriﬁed secreted tau
(eTau) or mock control (iPierian), Escherichia coli generated full-
length rTau383(0N4R) (rPeptide), synthetic human eTau4 peptide
(aa 2e68, 0N3R designation), scrambled human eTau4 peptide
control, or the equivalent mouse tau sequence (aa 2e57) (Neo-
biolab), or with 1, 10, or 30 mg/mL protein A puriﬁed tau antibodies
PHF1 andMC1 (PeterDavies), IPN002or anti-mouse IgG. Treatments
were diluted in basal media (Neurobasal media with Glutamax and
B27, Invitrogen) and incubated on neurons for a total of 20 days;
conditionedmediawas harvestedevery5days, and treatmentswere
added again, for a total of 20 days of exposure. Conditioned media
was stored at 80 C until day 20 end of assay for full time course
enzyme-linked immunosorbent assay (ELISA) analysis, and cells
were lysed in 50 mL M-PER (ThermoScientiﬁc) or 50 mL Buffer RLT
(Qiagen) for protein or messenger RNA (mRNA) analysis.
2.7. Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) activity in in vitro conditioned
media from iPSC-CN and human primary cortical cultures was
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(Sigma). Five day conditioned media of 25 mL or 50 mL was assayed
with an equal volume LDH reagent and incubated for 30 minutes at
room temperature. Plates were read on plate reader at 490 nm.
2.8. Human sAPPa and Ab40 and Ab42 ELISAs
Human sAPPa and Ab40 and Ab42 protein levels were measured
in primary human cortical neuron conditioned media collected
every 5 days over a 20-day treatment period using speciﬁc ELISA
assays (Invitrogen #KHB0051, MilliporeEMD #EZHS40, and Milli-
poreEMD #EZHS42 respectively).
2.9. Mouse Ab40 and Ab42 ELISAs
Mouse Ab protein levels were measured in mouse cortical brain
homogenate or ISF using mouse Ab40 and/or Ab42 ELISAs (Immuno-
Biological Laboratories #JP27720 and #JP27721). The mouse Ab42
ELISA lacked the sensitivity to reliably detect Ab42 in brain tissue.
2.10. Gene expression
Cultured neurons were lysed in Qiagen Buffer RLT and RNA iso-
lated using an RNeasy kit (Qiagen). Complementary DNAwas reverse
transcribed using the SuperScript VILO cDNA Synthesis Kit (Life
Technologies). Quantitative real time polymerase chain reaction was
performed using TaqMan Gene Expression Assays and Taqman
Expression Master Mix (Life Technologies) on an Applied Biosystems
HT 7900. Total MAPT, BACE1, ADAM9, ADAM10, ADAM17, APP, PSEN1,
and PSEN2 mRNA expression levels were normalized to RPLPO
(housekeeping gene)mRNAexpression levels and analyzed using the
DDCT method for relative expression. Invitrogen Taqman Gene
Expression Assays used Cat#4331182 individual ID # MAPT
Hs00902194_m1 (for all isoforms MAPT); BACE1 Hs01121195_m1;
ADAM9 Hs00177638_m1; ADAM10 Hs00153853_m1; ADAM17
Hs01041915_m1; APP Hs01041915_m1; PSEN1 Hs00997789_m1;
PSEN2 Hs01577197_m1; and RPLPO (Cat#4333761T). A probe
recognizing only the 2N4R/1N4R/2N3R/1N3R isoforms of MAPT
Hs00213484_m1 was used with MAPT Hs00902194_m1 to distin-
guish fetal 0N3R MAPT from other MAPT isoforms in both primary
human cultures and iPSC-CN cultures.
2.11. Western blots
Cultured primary human neurons were lysed in M-PER Buffer.
Cell lysates, primary cortical neuron conditioned media and iPSC-
CN conditioned media, were diluted in 2X Laemmli reducing
buffer, boiled, separated on NuPage gels, and transferred to nitro-
cellulose using iBlot. Western blots were blocked (LiCor) and pro-
bed with antibodies, IPN001 or IPN002 (1 mg/mL), HT7 (1 mg/mL),
PHF1 (1 mg/mL), Dako tau (1:3000), b-actin (1:5000), a-tubulin
(1:10,000), APP (1:1000 Sigma), and anti-mouse 680 or anti-rabbit
800 secondary antibodies (1:10,000, LiCor), analysis by Odyssey SA
software (LiCor).
2.12. Animals
Two transgenic human tau mouse models were used in these
studies. Experiments were conducted in accordance with the Na-
tional Institutes of Health Guide for the Care and Use of Laboratory
Animals guidelines and were approved by the Institutional Animal
Care and Use Committee. Schematic depicting overall study plans
provided in Supplementary Fig. 3.
The 8-week study used homozygous JNPL3 mice (Taconic,
Tg(Prnp-MAPT*P301 L)JNPL3Hlmc) as described by Lewis et al.(2000). The in-life study was conducted by Brains On-Line. In
brief, the JNPL3 line overexpresses human 0N4R tau containing the
most common frontotemporal dementia (FTDP-17) mutation P301L
on a C57BL/6, DBA/2, SW mixed background, driven by the prion
promoter. Homozygous JNPL3 mice express transgenic tau at levels
about 2-fold over endogenous tau and demonstrate motor and
behavioral deﬁcits as well as age dependent development of NFT
(Lewis et al., 2000).
The 26-week study used tau-4R/2N-P301L (van Leuven) mice as
described by Terwel et al. (2005). The in-life study was conducted
by reMYND. In brief, human 2N4R tau containing the FTDP-17
mutation P301L was overexpressed by the mouse thy1 promoter
on a pure Friend Virus B-type susceptibility genetic background.
Mice display an age dependent hyperphosphorylation of tau, tau
aggregation, and tangle formation with concomitant development
of motor defects.
2.12.1. The 8-week study (JNPL3 P301L mice)
Female JNPL3 mice aged 3.5 months old were treated weekly
with a single dose of 60 mg/kg irrelevant IgG1 or IPN002 antibody
for 8 weeks by an intraperitoneal injection volume of 10 mL/kg. At
the end of the study, mice were anesthetized using isoﬂurane (2%,
800mL/min O2) and stereotactically implanted with a microdialysis
probe in the ventral hippocampus, a polyacrylonitrile membrane
with 3mm exposed surface and 1megadalton cutoff (BrainLink, the
Netherlands). Bupivacain and/or epinephrine was used for local
analgesia and fynadine or carprophen for perioperative and/or
postoperative analgesia. Push-pull microdialysis sampling was
performed 24 hours after implantation surgery. Animal probes
were connected with FEP tubing to a microperfusion pump (Har-
vard PHD 2000 Syringe pump) and perfused with artiﬁcial CSF
containing 147 mM NaCl, 3.0 mM KCl, 1.2 mM CaCl2 and 1.2 mM
MgCl2, and 0.15% BSA at a ﬂow rate of 0.75 mL/min. Microdialysis
samples were collected over 60 minutes; basal samples were
collected after stabilization. Dialysis ISF samples were centrifuged
at 15,000 rpm for 15 minutes at 4 C. The animals were sacriﬁced
immediately following microdialysis sampling and terminal brain,
plasma, and CSF were collected (Brains On-Line).
2.12.2. The 26-week study (tau-4R/2N-P301L van Leuven mice)
Female mice aged 3e4 months old were treated weekly by an
intraperitoneal injection (10 mL/kg) of 20 mg/kg irrelevant IgG1 or
IPN002 antibody for up to 26 weeks (reMYND). At the study end,
mice were sacriﬁced and serum, CSF, and brain were collected. CSF
was collected via an incision in the neck muscle and drawn through
a puncture with a 26-gauge needle from the cisterna magna then
centrifuged at 10,000g/10 minutes at 4 C. Brain regions were
dissected from the left hemisphere (cerebellum, cortex, hippo-
campus, and hindbrain) for each mouse and homogenized in TBS
(Sigma) (1:10 wt/vol) then centrifuged at 10,000g/10 minutes at
4 C. Brain fraction homogenates were diluted to 1 mg/mL in TBS
and total protein concentration determined by BCA Assay (Pierce);
to generate a soluble fraction a portion of each homogenate was
further spun 1 hour at 100,000g (4 C) and soluble supernatants
collected. Friend Virus B-type susceptibility wild-type cortex was
provided by reMYND.
2.13. Tau ELISAs
2.13.1. Free-tau ELISA
We designed a homogeneous alphascreen (Perkin Elmer) assay
to measure tau not bound by IPN002 in mouse ISF and CSF and in
primary human cortical culture conditioned media and lysates. The
tau antibodies used are HT7 (aa 159e163) and the N-terminal tau
antibody IPN001 (aa 15e24) which competes with IPN002 binding
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IPN001 is biotinylated, and HT7 is conjugated to AlphaLISA acceptor
beads (Perkin Elmer). Samples are incubated overnight with both
antibodies. Streptavidin-coated acceptor beads (Perkin Elmer) are
added for 30 minutes and then the plate is read on Envision plate
reader (Perkin Elmer) at excitation 630 nm, emission 615 nm. Tau
levels were interpolated from an 8 point tau protein (rTau383,
0N4R) standard curve and analyzed using linear curve ﬁt in Excel.
2.13.2. Total-tau ELISA
The total-tau ELISA uses the tau antibodies HT7 (aa 159e163) to
capture and biotinylated BT2 (aa 194e198) for detection. HT7
diluted in PBS is coated on high binding ELISA plates (Costar-
Corning) at 1 mg/mL overnight at 4 C and plates blocked with 1%
Casein (VectorLabs)/PBS for 2 hours at room temperature. Samples
are diluted in 0.1%Casein/PBS and incubated overnight at 4 C. Tau
levels detected with 1 hour incubation with biotinylated tau anti-
body BT2, followed by addition of Streptavidin-HRP (Southern
Biotech) and then 3,30,5,50-tetramethylbenzidine substrate (TMB)
(ThermoScientiﬁc), assay was stopped with 1 M sulfuric acid
(Sigma), and the absorbance read on a Beckman plate reader at
450 nm. Tau levels were interpolated from an 8 point tau protein
(rTau383, 0N4R) standard curve diluted in 0.1%Caesin/PBS and
analyzed using 4-Parameter Sigmoidal Curve Fit (GraphPad Prism).
2.14. Tau binding assay
To measure the kD of various tau antibodies, high binding ELISA
plates were coated overnight at 4 C with 100 ng of recombinant
Tau383(0N4R) or puriﬁed eTau (iPierian) diluted in PBS; wells were
then blocked with 1% casein/PBS for 2 hours at room temperature.
Tau antibodies (IPN001, IPN002, MC1, and PHF1) were diluted to
10 mg/mL in PBS/0.1% casein and 12-point titrations generated,
added to the plate, and incubated 2 hours at room temperature.
After washing with 0.05%Tween-20 (Sigma)/PBS, detection anti-
body goat anti-mouse HRP (Southern Biotech) diluted 1:2000 in
PBS/0.1% casein was added and incubated at room temperature for
1 hour. Wells were washed as mentioned previously, and TMB
substrate (ThermoScientiﬁc) added, assay was stopped with 1 M
sulfuric acid, and absorbance read at 450 nm; kD was calculated
based on nonlinear regression analysis (GraphPad Prism).
2.15. Free IPN002 levels in CSF and ISF
Tomeasure the amount of free IPN002 inmouse CSF or ISF, high
binding ELISA plates were coated overnight at 4 C with 100 ng of
recombinant Tau383(0N4R) diluted in PBS; wells were then
blocked with 1% casein/PBS for 2 hours at room temperature. CSF
or ISF was diluted 50- or 200-fold in PBS/0.1% casein. Coated plates
were washed twice with PBS, then diluted CSF or ISF samples were
added to the plate in duplicate and incubated for 2 hours at room
temperature. After washing with 0.05%Tween-20 (Sigma)/PBS,
detection antibody goat anti-mouse HRP (Southern Biotech)
diluted 1:2000 in PBS/0.1% casein was added and incubated at
room temperature for 1 hour. Wells were washed as mentioned
previously, and TMB substrate (ThermoScientiﬁc) added, assay
was stopped with 1 M sulfuric acid, and absorbance read at
450 nm; IPN002 amounts calculated based on dilution factor and
linear regression analysis equation of the IPN002 standard titra-
tion (GraphPad Prism).
2.16. Electrophysiology
Wholeecell patch-clamp recording was performed on primary
human cortical cultures and familial AD PSEN1 (A260V) iPSC-CNcultured on a monolayer of normal human astrocytes (Lonza) us-
ing a micropipette (2e5 MOhm) ﬁlled with solution containing
(mM): K-methyl-sulfate (140), NaCl (10), CaCl2 (1), Mg-ATP (3); Na-
GTP (0.4), EGTA (0.2), HEPES (10), phosphocreatine (10) with
adjusted pH ¼ 7.3, and mOsm ¼ 305. Neurons were perfused
(1e2 mL/min) with artiﬁcial cerebral spinal ﬂuid containing (mM):
NaCl (140), KCl (2.5), MgCl2 (2) CaCl2 (2), Hepes (10), D-Glucose (10),
sucrose (20), adjusted pH ¼ 7.3e4 mOsm ¼ 310. Recordings were
made using pClamp-10.3 data acquisition software (Molecular De-
vices) and MultiClamp 700B ampliﬁer (Axon Instrument, Foster
City, CA, USA). Puff application of eTau, full-length rTau383 (0N4R),
and buffer or mock protein controls was performed using MiniS-
quirt micro-perfusion system (AutoMate, Berkeley, CA, USA). Bath
application of eTau, IPN002 antibody, and buffer controls was per-
formed for other recordings. Off-line data analysis used Clampﬁt
10.2 analysis software (Molecular Devices). Recordings were con-
ducted at 34 Ce37 C.
2.17. Statistical analysis
Statistics were determined using GraphPad Prism software. Data
are expressed as mean  standard deviation on an n ¼ 3 (unless
otherwise noted in ﬁgure legends); experiments were repeated a
minimum of 4 times. Analysis of tau or Ab levels, comparing the
effects of one treatment versus control, at a single time point, were
done by 2-tailed unpaired t test with Welch correction. Analysis of
tau, Ab, and sAPPa levels involving repeated measures between
multiple treatment groups at different time points was done using
1-way analysis of variance with Tukey multiple comparison
correction, unless otherwise noted. When signiﬁcant (<0.05),
p-values are noted.
3. Results
3.1. Human MAPT knockdown reduces Ab (40 and 42) and
increases sAPPa levels in vitro in human primary cortical neurons
To better understand the relationship between Ab and tau, we
asked whether tau can alter levels of soluble, endogenous Ab pro-
duced from human neurons. Gene expression and Western blot
analysis of primary human neuronal cultures derived from fetal
tissue show that the cultures express neuronal APP695 and only the
embryonic (0N3R) isoform of tau, as well as BACE1, the 3 a-secre-
tase proteins (ADAM9, ADAM10, and ADAM17) and both PSEN1 and
PSEN2 (Supplementary Fig. 1AeC).
To demonstrate that our primary human neuronal cultures ex-
press and regulate Ab appropriately, we show that levels of Ab40
and Ab42 are lowered by a BACEi, a direct Ab processing inhibitor
(Supplementary Fig. 1D), and that siRNAs targeting both b- and
a-secretase are capable of modulating Ab and sAPPa levels,
respectively (Supplementary Fig. 1E and F).
To investigate the potential regulation of Ab40 and Ab42 by hu-
man tau, we reduced MAPT gene expression and tau protein levels
in our primary human cortical neuron cultures over 70% using
Accell MAPT siRNA pools (Fig. 1A). Under these conditions non-
targeting siRNA had no effect on Ab levels; MAPT knockdown
however resulted in a reduction of both Ab40 and Ab42 levels >50%
(Fig. 1B).
We then asked if tau affects a- and/or b-secretase, 2 proteases
opposed in Ab generation that compete for APP substrate. Colombo
et al. (2012) show that a- and b-secretase cleavage of their common
substrate APP is partially coupled in primary mouse neurons. We
conﬁrmed these results in primary human neurons, showing that
BACEi results in increased production of sAPPa (soluble APP cleaved
at the a-secretase site) in the conditioned media, Fig. 1C left, as well
Fig. 1. Human tau increases Ab and decreases sAPPa levels in vitro in primary human cortical cultures. Primary human neurons treated withMAPT, nontargeting (NT) siRNA or BACEi
for to 20 days. Conditioned media (CM) collected every 5 days, cells retreated, cell lysates collected at day 20. Each experiment repeated 6 times, n ¼ 3 for each condition; graphs are
STD on mean. (A) siRNA transfection decreases MAPT mRNA levels by 85%. Tau protein levels decreased 72% (Western blot quantiﬁcation shown normalized to b-Actin); both
compared with NT control. Day 20 data shown. (B) MAPT siRNA treatment decreases Ab40 levels by 54% (6546  262 pg/mLe3028  215 pg/mL ) and Ab42 levels by 68% (1356  43
pg/mLe432  64 pg/mL). Bars represent mean Ab levels shown as percent of NT control; error bars are standard deviation; ***p ¼ 0.0001 and ****p < 0.0001, by 2-tailed unpaired t
test Welch correction. (C) BACEi treatment increases sAPPa levels in CM by 35% (42  1 ng/mLe59  1.3 ng/mL); MAPT siRNA treatment increases sAPPa levels in CM by 42% (42  1
ng/mLe59  1.2 ng/mL). Bars represent sAPPamean levels as percent of control treatment value; error bars are standard deviation; vehicle versus BACEi, *p ¼ 0.0129; nontargeting
siRNA versus MAPT siRNA, ****p < 0.0001, by 2-tailed unpaired t test Welch correction. Abbreviations: Ab, amyloid-beta; BACEi, BACE1 inhibitor; mRNA, messenger RNA; sAPPa,
soluble amyloid precursor protein-a; siRNA, small interfering RNA; STD, standard deviation.
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Fig. 1C. Furthermore, treatment of primary human neuron cultures
with siRNAs directed against BACE1 and ADAM9/10/17 resulted in
opposing effects on cellular Ab and sAPPa levels (ELISA data
Supplementary Fig. 1E and F).
In our primary human neuron cultures, we reduced MAPT gene
expression and tau protein (Fig. 1A) levels over 70% using Accell
MAPT siRNA pools. Under these conditions nontargeting siRNA had
no effect on sAPPa levels; MAPT knockdown however resulted in a
42% increase in sAPPa (Fig. 1C right).
3.2. Secreted tau (eTau) identiﬁed from AD patientederived iPSC
cortical neuron conditioned media is composed of N-terminal tau
fragments
In light of these ﬁndings and recent data showing tau to be
secreted from human induced pluripotent stem cell (iPSC)-derived
cortical neurons (Chai et al., 2012), we characterized tau release
from our iPSC-CN derived from AD patients. To do so, we generated
iPSC from a skin biopsy taken from a familial presenilin-1 (A260V)
AD patient aged 50 years then differentiated and cultured iPSC-CN
for up to 108 days. To characterize eTau secretion from these iPSC-
CN, we collected conditioned media beginning at day 70 over time
for 96 hours. As shown in the tau Western blot in Fig. 2A, tau is
present in the conditioned media of iPSC-CN and quickly accumu-
lates over time.Toensure that the tau found in the conditionedmediawasnot the
result of cell lysis, we measured the LDH activity in the conditioned
media of several of our iPSC-CN lines listed inTable 1, and found all to
be free of cell lysis (Supplementary Fig. 2A). These data and an
absence of other high abundance cytoplasmic proteins such as
b-actin and a-tubulin (Supplementary Fig. 2B) in the conditioned
media together conﬁrm the lack of contamination by intracellular
proteins in iPSC-CN conditionedmedia. The tau releasewe observed
from our iPSC-CN is rapid, detectable within 2e5 minutes, and pla-
teaus over 24e96 hours (Fig. 2A). iPSC-CN tau secretion is not
modulated by Brefeldin A treatment, indicating that secretion is
occurring independently of the canonical secretory process (Fig. 2B).
Because iPSC-CNs derived from AD patient samples secrete tau
in the absence of neuronal lysis, we characterized the secreted tau
species identiﬁed in the media. To do so, we attempted to immu-
noprecipitate tau from the media (conditioned 3 days) of 70-day-
old iPSC-CNs derived from a familial presenilin-1 (A260V) AD
patient with either an N-terminal tau antibody (IPN002), a mid-
range tau antibody (HT7), or a C-terminal tau antibody (T46).
Each of these antibodies efﬁciently isolates cytoplasmic full length
tau (data not shown) but only IPN002 and HT7, not T46, were
capable of immunoprecipitating secreted tau (Fig. 2C). The C-ter-
minal tau antibody’s failure to isolate secreted tau is shown by
IPN001 Western blot analysis of the 3 immunoprecipitated prod-
ucts, indicating that tau is released from AD iPSC-CN predominately
as N-terminal fragments ranging from 20 to 28 kDa (Fig. 2D) with
Fig. 2. Tau is secreted as N-terminal fragments from AD patientederived iPSC cortical neurons (iPSC-CN). (A) IPN001 Western blot of tau fragments released over 96 hours into the
CM of fAD PSEN1 (A260V) iPSC-CN cultures. At time 0, media removed, cells washed with media, fresh growth media added, and CM harvested at described time points, lysates
harvested at ﬁnal time point. Graph of IPN001 Western blot quantiﬁcation normalized to total b-actin levels in lysate shows tau levels in the CM increasing with time. (B) fAD PSEN1
(A260V) iPSC-CN cultures were washed as described previously and treated 10 mg/mL Brefeldin A for 4 hours, CM and lysates harvested; IPN001 Western blot of CM normalized to
total b-actin levels in lysate show no difference in tau secretionwith Brefeldin A. (C) IPN001Western blot analysis of tau fragments immunoprecipitated from CM of iPSC-CN cultures
using tau region speciﬁc antibodies; nonconditioned media (media) immunoprecipitated as control for each antibody. (D) IPN001 Western blot of 4 main tau fragments (eTau)
afﬁnity isolated and puriﬁed from AD patient derived iPSC-CN CM with IPN002. (E) Sequence from LC/MS veriﬁed eTau 1, 2, 3, and 4 are aligned with 2N4R tau sequence. Ab-
breviations: AD, Alzheimer’s disease; CM, conditioned media; iPSC, induced pluripotent stem cells; LC/MS, liquid chromatography-mass spectrometry.
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consistent with reports showing that tau is secreted into AD patient
CSF as N-terminal fragments (Meredith et al., 2013). We have
conducted similar characterizations of eTau secreted from cortical
neuron from healthy control subjects and found a similar molecularweight range of eTau fragments as those found for AD patients (data
not shown).
To verify the 20e28 kDa bands as tau and to identify their
sequence, we afﬁnity isolated secreted tau from our iPSC-CN
conditioned media with the tau antibody IPN002 and conducted
Table 2
Antibody reactivity to full length or secreted eTau measured using a direct binding assay
Antibody Antigen Binding to rTau383 (0N4R) kD [M] Binding to secreted tau kD [M] Epitope (amino acids)
MC1 AD tau (conformational) 1.35  109 2.44  1010 7e9 and 313e322
IPN001 Aggregated tau 1.4  1010 1.51  1010 15e24
IPN002 Aggregated tau 1.61  1010 1.31  1010 15e24
PHF1 AD tau 1.05  109 Does not bind PS396/S404
Key: AD, Alzheimer’s disease.
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analysis on the 4 major IPN002-afﬁnity isolated, anti-tau reactive
bands shown in Fig. 2D.We also used intact protein LC/MS to ensure
we identiﬁed the end of the largest tau fragment. This analysis
conﬁrmed that secreted tau is a series of N-terminal tau fragments,
all lacking the C-terminal amino acids of tau, including the micro-
tubule binding repeats as shown in the sequence alignment in
Fig. 2E. We named the 4 major fragments eTau 1, 2, 3, and 4 and
refer to the pool of secreted tau as eTau (for extracellular tau).
Our iPSC-CNs only express the 0N3R embryonic isoform of tau
(Supplementary Fig. 1B), and LC/MS analysis conﬁrmed the n1 and
n2 inserts to be missing in the sequenced fragments, Fig. 2E. All
forms of eTau start at the second amino acid, alanine, with the N-
terminal methionine removed and the alanine acetylated. This is a
covalent modiﬁcation traditionally indicative of a cytosolic protein,
providing further evidence that eTau is released independent of the
canonical endoplasmic reticulum and/or golgi secretory process.
The 4major forms of eTauwe identiﬁed range in size from 67 amino
acids (aa 2e44,103e126, eTau4) to 171 amino acids (aa 2e44,
103e230, eTau1), Fig. 2E. Phosphorylation of eTau was rarely
detected but when found the residues phosphorylated were
consistent with phosphorylation of cytoplasmic tau at residues
threonine181 (p181), serine202 (p202), and threonine231 (p231).
We further characterized eTau by its reactivity with several tau
antibodies, speciﬁc afﬁnities are shown in Table 2. Both 0N4R re-
combinant full length tau-383 and eTau bind with high afﬁnity to
the N-terminal tau antibodies MC1 (a conformational speciﬁc tau
antibody) (Jicha et al., 1997) and IPN002 (generated against
aggregated tau, iPierian). Not surprisingly, eTau does not bind to the
C-terminal anti-phospho-tau antibody PHF1 (Jicha et al., 1997) in
either the tau binding assay (Table 2) or by Western blot
(Supplementary Fig. 2C), indicating that eTau lacks this phos-
phoepitope, as expected based on LC/MS analysis.
3.3. eTau regulates Ab (40 and 42) levels in vitro in primary human
neurons
We found that this pool of N-terminal eTau fragments is also
secreted fromhumanprimary cortical neurons at concentrations up
to 3e4 nM, when allowed to condition for 5 days (data not shown).
Total tau ELISA of the conditionedmedia of humanprimary neurons
conﬁrmed this tau secretion and demonstrated that MAPT knock-
down in these primary human neurons signiﬁcantly reduces
secreted eTau levels in the conditioned media over time when
compared with nontargeting siRNA control (Fig. 3A).
To determine if eTau plays a role in regulating Ab40 and Ab42, we
treated primary human neurons for 20 days (media and treatments
replaced every 5 days) with afﬁnity puriﬁed eTau from AD patient
derived iPSC-CN or mock protein control and saw a dose and time-
dependent (as early as 10 days at 500 nM) increase in levels of Ab40
and Ab42 (Fig. 3B). The changes in Ab levels are small but repro-
ducible over multiple experiments and are statistically signiﬁcant.
Because the conditioned media from primary human neurons,
when allowed to condition on cells for 5 days, already contains
secreted eTau at concentration up to 3e4 nM, a large excess of
puriﬁed secreted eTau (500 nM) appears to be required to generatethese additional small changes. Less eTau was needed (<50 nM) to
see similar increases in Ab40 and Ab42 when protein was applied to
primary human cortical cultures in which MAPT was reduced by
>75% with siRNA transfection (data not shown). Similar experi-
ments conducted with up to 1 mMof full-length rTau383 (0N4R) did
not affect Ab levels (data not shown), suggesting an eTau speciﬁc
regulation of Ab levels.
3.4. eTau regulates sAPPa levels in vitro in primary human neurons
Our data indicate that eTau may be affecting how Ab is pro-
duced. To understand how eTau is affecting Ab production at the
mRNA level we measured the gene expression of APP, BACE1,
ADAM9, ADAM10, and ADAM17 in human primary neurons but did
not detect any signiﬁcant gene expression changes after treatment
with either MAPT siRNA, puriﬁed secreted eTau, or tau binding
antibodies (gene expression data not shown).
The addition of eTau to primary human neurons for 20 days
caused a small but signiﬁcant, dose-dependent decrease in sAPPa
levels (Fig. 3C). The simultaneous increase in Ab with the decrease
in sAPPa indicates that eTau is affecting the production of Ab in
neurons.
3.5. eTau binding antibodies reduce Ab (40 and 42) and increase
sAPPa levels in vitro in primary human neurons
We tested each of several antibodies for binding afﬁnity to tau
and eTau. As expected, all tau antibodies tested bound with good to
excellent Kd’s and as expected IPN001, IPN002 bound to eTau,
whereas PHF1 did not bind eTau, Table 2. Unexpectedly, we found
that MC1 bound with high afﬁnity to not only tau but also eTau,
Table 2. This was unexpected because MC1 is reported to bind to a
conformational epitope comprised both aa 7e9 and aa 313e322,
but aa 313e322 are not present on eTau. This suggests that MC1 can
also bind to eTau as well as to the conformation epitope as
described previously. Peter Davies has also found that MC1 binds to
the N-termini of tau, in the absence of the C-terminal epitope
(personal communication). To conﬁrm therefore that eTau regu-
lates Ab, we treated our human primary cortical cultures with
various tau antibodies. We used the eTau binding antibodies
IPN002 and MC1, as well as PHF1, shown not to bind to eTau. We
found that when added to cortical neurons, MC1 and IPN002 both
time dependently reduced Ab40 and Ab42 levels, whereas the IgG
control and PHF1 had no effect (Fig. 4A). Additionally, eTau binding
antibodies (MC1 and IPN002) increased levels of sAPPa over time,
whereas PHF1 did not (Fig. 4B). APPWestern blots of the cell lysates
of IPN002 treated primary human cortical cultures conﬁrm these
ELISA results, showing a slight increase in APP CTF-a when
compared with IgG control (Supplementary Fig. 1C).
To demonstrate that our IPN002 antibody is acting extracellu-
larly, speciﬁcally binding, and neutralizing secreted and not intra-
cellular tau, we used our IPN002-free-tau ELISA assay to analyze the
conditioned media and lysate of primary human cortical neurons
treatedwith IPN002. This is an IPN002 competitive tau assay, which
only detects tau not already bound by IPN002. Analyzing the
conditioned media of primary human neurons treated with either
Fig. 3. eTau increases Ab and decreases sAPPa levels in human primary cortical neurons in vitro. Experiments done on primary human cortical neurons, treatments present for
20 days in total; conditioned media harvested and cells retreated every 5 days with siRNAs or puriﬁed eTau protein. Total tau (A), Ab40 and Ab42 (B), and sAPPa (C) ELISAs ran on day
5, 10, 15, or 20 CM. Each experiment repeated 6 times, n ¼ 3 for each condition; graphs are STD on mean. (A) Human total tau ELISA showsMAPT siRNA reduces secreted tau levels by
greater than 50% by day 15 compared with control siRNA (0.6  0.1 AUe0.25  0.04AU); ****p < 0.0001 by 1-way ANOVA with Tukey multiple comparison correction. (B) Afﬁnity
puriﬁed human eTau treatment gradually increases both Ab40 and Ab42 levels above mock control (38% and 40%, respectively, at 500 nM) by day 20 in CM. Effects are dose and time
dependent; Ab40 ****p < 0.0001, *p ¼ 0.0113; Ab42 ****p < 0.0001, by 2-way ANOVA with Tukey multiple comparison correction. (C) Afﬁnity puriﬁed human eTau lowers sAPPa
levels; day 20 data shown. Treatment of human primary neurons with 500 nM eTau for 20 days slightly but signiﬁcantly decreases sAPPa levels by 14% (39.55  0.77 ng/mL
downe33.94 1.5 ng/mL). eTau effects are dose dependent and time dependent (data not shown); 500 nM vehicle versus 500 nM secreted tau ****p < 0.0001, by 1-way ANOVAwith
Tukey multiple comparison correction. Abbreviations: Ab, amyloid-beta; ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; eTau, extracellular tau; sAPPa,
soluble amyloid precursor protein-a; siRNA, small interfering RNA; STD, standard deviation.
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Fig. 4. eTau antibodies decrease Ab40 and Ab42 and increase sAPPa levels in vitro in primary human cortical cultures. Experiments done onprimary human cortical neurons, treatments
present for 20 days in total; conditionedmedia harvested and cells retreated every 5dayswith tau antibodies. Ab40 andAb42 ELISA (A), sAPPa ELISA (B), and free-tau ELISAassay (C). Each
experiment repeated 6 times, n ¼ 3 for each condition. (A) Secreted tau binding antibody IPN002 reduces Ab40 and Ab42 levels up to 43% and MC1 up to 40%. Nonsecreted tau binding
antibody PHF1 has no effect on Ab levels. Antibody effects are time dependent; graphs are STD on mean; * d10, IgG versus tau antibody p < 0.0001; y d15, IgG versus tau antibody p<
0.0001; zd20, IgGversus tauantibodyp<0.0001, by1-wayANOVAwith Tukeymultiple comparison correction. (B) IPN002 increases sAPPa levelsup to37%andMC1upto28%by10days
of treatment; PHF1 has no effect on sAPPa levels. d10, IgG versus tau antibody *p< 0.0001; d15, IgG versus tau antibody yp< 0.0001; d20, IgG versus tau antibody zp< 0.0001 by 1-way
ANOVAwith Tukey multiple comparison correction. (C) Free-tau ELISA assay of lysate and CM harvested after 20 days of treatment shows IPN002 engages 92% eTau secreted into the
media (free-tau levels in IgG treatedCM1.9090.28AUvs. IPN002 treatedCM0.1430.018AU); lysate levels of tau areunchangedwith IPN002; STDonmeanhuman tau free of IPN002
shownas% change fromcontrol; ** IgGversus IPN002p¼0.0083by2-tailedunpaired t testwithWelchs correction.Abbreviations:Ab, amyloid-beta;ANOVA, analysis of variance; ELISA,
enzyme-linked immunosorbent assay; eTau, extracellular tau; sAPPa, soluble amyloid precursor protein-a; STD, standard deviation.
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20 days, we found that the vast majority of eTau in the conditioned
media of these cultures was bound to IPN002, measured as a sig-
niﬁcant decrease in IPN002-free tau (Fig. 4C, right). Analyzing the
lysates of these cultures, we found no change in free tau levels with
IPN002 treatment (Fig. 4C, left). This indicates that IPN002 is not
entering the cell in sufﬁcient quantities to bind and/or neutralize
intracellular tau, and suggests that the antibody’s observed effect
on Ab levels is through its interaction with secreted eTau.
These results suggest that eTau plays a role in modulating Ab
levels in vitro. In contrast to the b-secretase inhibitor which rapidly
(1 day) and dramatically (75%e85%) lowers Ab levels (Supplementary
Fig. 1D), IPN002 and MC1 lower Ab levels more gradually (10 days)
and modestly (30%e40%) (Fig. 4A). The gradual effect of these eTau
binding antibodies is indicative of a modulatory rather than a direct,
inhibitory role.
3.6. Human synthetic eTau 4 increases Ab (40 and 42) levels in vitro
in primary human cortical neurons
In vivo studies in APP transgenic mice show that reductions of
endogenous murine tau do not impact Ab levels (Ittner et al., 2010;
Roberson et al., 2007, 2011). Therefore, to further understand ourﬁndings in the context of these studies involving mouse tau, we
asked if human andmouse tau affect Ab production differently. To do
so, we generated a synthetic version of human eTau 4, a 67 amino
acid peptide corresponding to the shortest secreted N-terminal tau
fragment identiﬁed by LC/MS from iPSC-CN media. We also syn-
thesized a peptide corresponding to the equivalent amino acid
sequence inmouse tau (Fig. 5A). Because both our ADpatient derived
iPSC-CN cultures and our primary human cortical cultures predom-
inately express embryonic 0N3R tau (Supplementary Fig. 1B) we did
not include the n1 and n2 inserts in these synthetic sequences.
Notably, mouse tau is missing the human tau insert, amino acids
17e28, which encompasses most of the IPN002 epitope (aa 15e24).
We treated primary human neurons with either the human or
mouse eTau 4 peptide or a scrambled control peptide and looked for
differential effects on Ab levels. By using synthetic versions of the
sequences, we eliminated any potential posttranslational differ-
ences between the 2 species tau and treated the same primary
human neuronal cultures for direct comparison. Under these con-
ditions, human eTau 4 treatment signiﬁcantly increased Ab40 and
Ab42 levels (18% and 26% respectively compared with scrambled
control), although treatment with mouse eTau 4 did not increase
Ab40 and Ab42 levels (Fig. 5B). Again, the increases in Ab levels with
human eTau4 are small but reproducible and highly signiﬁcant.
Fig. 5. Human tau insert increases Ab levels in primary human cortical neurons. (A) Alignment of N-terminal human and mouse tau sequences comparing human eTau 4 sequence
with 11 amino acid human tau insert (aa 17e28) to mouse eTau 4 sequence. (B) Synthetic human eTau 4 peptide and a peptide consisting only of the human tau insert (aa 17e28)
both increase Ab40 and Ab42 levels signiﬁcantly above scrambled control peptide by speciﬁc ELISAs. Human eTau 4 peptide treatment (500 nM) increases Ab40 and Ab42 levels above
scrambled control; Ab40 18% (scrambled peptide 7116.3  147 pg/mL to human eTau 4 8402  111 pg/mL) and Ab42 26.4% (scrambled peptide 1216  98 pg/mL to human eTau 4 1538
 57 pg/mL). Human tau insert peptide (500 nM) (aa 17e28) increases Ab40 16% (scrambled peptide 7116.3  147 pg/mL to 8286  236 pg/mL for aa 17e28) and Ab42 27% (scrambled
peptide 1216  98 pg/mL to 1546  39 pg/mL for aa 17e28 peptide). Effects are dose and time dependent (data not shown); bars represent mean pg/mL Ab40 and Ab42 with STD;
Ab40 ****p < 0.0001; Ab42 ****p < 0.0001 by 1-way ANOVA with Tukey multiple comparison correction. Experiments done on primary human cortical neurons, 500 nM peptides
present for 20 days in total; conditioned media harvested and cells retreated every 5 days, each experiment repeated 4 times, n ¼ 3 for each condition. Abbreviations: Ab, amyloid-
beta; ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; eTau, extracellular tau; STD, standard deviation.
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additional peptide encompassingonly the human tau insert,we show
that the 12 amino acids missing from mouse tau are capable of
increasing Ab40 andAb42 to the same level as the entire human eTau4
peptide (Fig. 5B). These data conﬁrm that human eTau increases Ab
production and suggest that the modulation of Ab production is hu-
man eTau speciﬁc via an activity conferred by the human tau insert.
3.7. The eTau antibody, IPN002, reduces Ab (40 and 42) levels
in vivo
To test our hypothesis in vivo, we ﬁrst used the transgenic P301L
tauopathy model (JNPL3, Taconic) that releases mutant human tau
into the ISF (Fig. 6A). We found that tau is present in the ISF of these
mice at a truncated size of approximately 25 kDa, Supplementary
Fig. 2D, similar to eTau found in the AD patient cortical neuron
conditioned media. This is in contrast to the ﬁndings by Yamada
et al. (2011) showing full-length tau in the ISF of P301L mice. We
treated 3.5-month-old JNPL3 mice weekly with either IgG1 control
or IPN002 for 8 weeks, collected ISF at 5.5 months of age, and
measured the levels of IPN002 antibody, IPN002-free tau, and Ab40
and Ab42. To verify that IPN002 entered the central nervous system(CNS), we measured levels of IPN002 in the plasma and ISF of each
animal at study termination and found IPN002 present in the ISF in
all cases (Fig. 6B). Additionally, we found that IPN002 bound almost
all the human mutant tau available in the ISF, measured by a 94%
reduction in the free tau levels (Fig. 6C). Ab40 and Ab42 analysis of
the animal’s ISF at the end of the 8-week treatment showed IPN002
treatment reduced endogenous mouse Ab40 and Ab42 levels by
approximately 25% (Fig. 6D).
We validated these initial ﬁndings in a second transgenic P301L
tauopathy model, using the tau-4R/2N-P301L (van Leuven) mice, in
which secreted human tau levels increase with age, (Fig. 6E). In this
model, 3.5-month-old animals have <10 ng/mL human tau in their
CSF, by 9.5 months their CSF tau levels increase to an average of
30 ng/mL (Fig. 6E). We treated these mice weekly, for up to
26 weeks, with 20 mg/kg IgG1 control or IPN002. To verify that
IPN002 entered the CNS, we measured levels of IPN002 in the
plasma and CSF of each transgenic animal at 9.5 months and found
IPN002 present in the CSF in all dosed animals (Fig. 6F). CSF analysis
by IPN002-free-tau ELISA assay conﬁrmed that human mutant tau
was fully engaged by IPN002, measured by a 98% reduction in free
tau levels, Fig. 6E, IPN002 treated compared with IgG1 control-
treated mice.
Fig. 6. IPN002 binds secreted tau and reduces Ab levels in vivo. The 8-week study in P301L JNPL3 tau transgenic mice. (A) Human tau is present in ISF of P301L (JNPL3) tau
transgenic mice (n ¼ 5 animals). Bars represent mean ng/mL human tau by total tau ELISA; error bars STD; 2-tailed unpaired t test with Welch correction ****p < 0.0001. (B) IPN002
antibody levels measured in plasma and ISF of each P301L (JNPL3) mouse, in plasma IPN002 levels were 338.9  10 mg/mL, in ISF IPN002 levels were 293.6  21 ng/mL; n ¼ 15
animals for IPN002, n ¼ 6 animals for IgG; STD on mean levels of IPN002. (C) IPN002 decreases human free tau by 94% in ISF (IgG1 treated 8.78  6.49 ng/mL vs. IPN002 treated
0.71339  0.845 ng/mL); STD on mean levels human tau free of IPN002 in ISF by free-tau ELISA; 2-tailed unpaired t test with Welch correction ****p < 0.0001. (D) IPN002 treatment
signiﬁcantly decreases levels of mouse Ab40 by 24% (from 84  17 pg/mL to 64  9 pg/mL) and Ab42 by 25% (from 33  6 pg/mL to 25  4 pg/mL) in mouse ISF at the end of the 8-
week study. Bars represent mean mouse Ab levels as percent of control with STD; Ab40 ***p ¼ 0.0005; Ab 42 ***p ¼ 0.0003 by 2-tailed unpaired t test with Welch correction. The 26-
week study in P301L van Leuven transgenic mice. (E) In a 26-week study, human P301L tau levels signiﬁcantly increase with age (3-fold) in CSF measured at 3.5 months (n ¼ 10
animals) and at the 9.5 months end the study (n ¼ 28). By 9.5 months end of study, IPN002 antibody treatment of transgenic animals (n ¼ 32) engaged 97% of secreted human
mutant tau in CSF, compared with IgG1 control treated mice (n ¼ 32 animals), measured by free-tau ELISA, mean ng/mL tau free of IPN002 in CSF of each mouse (IgG1 treated 30.566
 21.8 ng/mL vs. IPN002 treated 1.150  1.61 ng/mL), error bars are STD, 9.5 months IgG1 versus 9.5 months IPN002 ****p < 0.0001, statistics are 1-way ANOVA with Tukey
correction. (F) Mean IPN002 antibody levels in the 9.5-month-old transgenic mice were 135.5  32 mg/mL in plasma (n ¼ 31) and 130.4  35 ng/mL in CSF (n ¼ 21); STD on mean
levels of IPN002 in plasma and CSF. (G) Ab40 levels are increased by 57% with age in the soluble fraction of the cortex of transgenic mice, measured in 3.5 month old versus 9.5 month
old P301L van Leuven mice (14.35  0.78 pg/mLe22.52  2.7 pg/mL). Ab40 levels are increased by 72% with disease progression in transgenic mice (13.11  0.25 pg/mLe22.52  2.7
pg/mL) comparing Ab40 levels in 9.5-month-old wild type C57/BL6 mice with 9.5 months P301L van Leuven mice. IPN002 antibody treatment signiﬁcantly reduces Ab40 levels in the
transgenic mice by 22% (22.52  2.7 pg/mLe17.64  2 pg/mL); ****p < 0.0001, 1-way ANOVA with Tukey correction. Mouse Ab40 levels do not change with age in wild type C57/BL6
mice approximately 4.3 monthse9.5 months. Bars are mean pg/mL mouse Ab40; error bars are STD. Abbreviations: Ab, amyloid-beta; ANOVA, analysis of variance; ELISA, enzyme-
linked immunosorbent assay; CSF, cerebrospinal ﬂuid; ISF, interstitial ﬂuid; STD, standard deviation.
J. Bright et al. / Neurobiology of Aging 36 (2015) 693e709704We measured Ab40 levels in both the total homogenate and the
soluble fraction of the hindbrain (data not shown) and cortex; the
results were consistent between fractions and brain regions. As
shown in Fig. 6G, Ab40 levels in the soluble fraction of P301L mousecortex increase from 14.4 pg/mL at 3.5 months to 22.5 pg/mL at
9.5 months (IgG1 control group). This substantial increase in levels
of murine Ab40 in a tau mouse model may be because of either age,
continued human tau expression, or a combination of both. To
J. Bright et al. / Neurobiology of Aging 36 (2015) 693e709 705distinguish between these possibilities, we measured Ab40 levels in
the soluble fraction of the cortex of wild type C57/BL6 mice at
4.3 months and 9.5 months of age (Fig. 6G) and saw no change in Ab
with age. This suggests that the observed increase in mouse Ab over
time in this P301L tau mouse model is because of human tau
expression.
To determine if elevated levels of Ab40 could be lowered with
the human eTau binding antibody IPN002 we compared the Ab40
levels of IgG1 and IPN002 treated mice and found that IPN002
treatment signiﬁcantly reduced levels of soluble mouse Ab40 by
>25%, Fig. 6G. Together these data suggest that human tau
released from neurons modulates Ab production both in vitro and
in vivo.3.8. TTX treatment lowers Ab and eTau levels in primary human
cortical neurons in vitro
How does eTau modulate Ab production? In AD, secreted tau is
hypothesized to be released presynaptically and then taken up
postsynaptically, inducing spread, tau pathology, neuronal
dysfunction, and neuronal hyperactivity. Kamenetz et al. (2003)
showed that picrotoxin induced hyperactivity in hippocampal sli-
ces dramatically elevated Ab40 and Ab42 although TTX treatment
was able to lower Ab levels; Cirrito et al. (2005), (2008) found a
similar link between heightened neuronal and synaptic activity and
increased Ab production in living mouse ISF.
To determine whether our observed increase in Ab could be
the result of eTau induced neuronal hyperactivity, we treated
our primary human cortical cultures with the sodium channel
blocker TTX. As has been shown previously in vitro and in vivo,
TTX is capable of signiﬁcantly reducing soluble Ab40 and Ab42
in a dose and time-dependent manner (Fig. 7A), with no
change to cell viability (data not shown). In these same cul-
tures, eTau levels analyzed in the conditioned media of the TTX
treated neurons were also reduced, by 60%, after 10 days of TTX
treatment (Fig. 7B). eTau in the conditioned media of neurons
is signiﬁcantly reduced by day 10 of TTX treatment; however,
Ab levels are not affected until day 15, suggesting that sup-
pressing neuronal activity reduces eTau levels and subsequently
alters Ab production.3.9. eTau induces hyperactivity in human neurons
Increased neuronal activity potentiates Ab levels in vitro and
in vivo. This suggests that one mechanism by which eTau can
modulate Ab production is through increasing neuronal activity.
To test this hypothesis, we performed wholeecell patch-clamp
recordings to determine the effect eTau has on cortical
neuron activity. Application of eTau increased the activity of
both iPSCs-derived cortical neurons and primary human cortical
neurons (Fig. 7C). Interestingly, application of full length tau
(rTau383, 0N4R) at signiﬁcantly higher concentrations (up to
3 mM) failed to produce any changes in neuronal activity similar
to those caused by eTau treatment. This suggests that the eTau
mediated neuronal activity effects may involve a speciﬁc
interaction of the eTau protein with cortical neurons. This
interaction appears to be speciﬁc to the N-terminal region of
tau as it cannot be replicated with full length tau (rTau383,
0N4R). To test this hypothesis, we preincubate eTau with the
neutralizing antibody IPN002 to block eTau mediated hyperac-
tivity. At a 10:1 molar ratio of IPN002 to eTau, IPN002 inhibited
eTau mediated hyperactivity (Fig. 7D). Together, these results
suggest that eTau can modulate Ab levels by promoting cortical
neuron hyperactivity.4. Discussion
In this study, we describe the identiﬁcation of a novel secreted
N-terminally truncated tau species (eTau), present both in vitro and
in vivo, and show that these secreted tau fragments can regulate Ab
production. We initially puriﬁed eTau from the conditioned media
of AD patientederived cortical neuron cultures and found that
secreted tau is composed predominantly of N-terminal fragments
of tau. In vitro, we show that treating primary cortical cultures with
eTau simultaneously increases Ab levels while decreasing sAPPa
levels. Globally, reducing tau with MAPT siRNA or treating neurons
with neutralizing eTau antibodies lowers Ab levels and increases
sAPPa levels in parallel. Importantly, we validated these ﬁndings
in vivo in 2 tau transgenic (P301L) mouse models. Levels of human
tau are elevated in the ISF and CSF of the tau transgenic animals;
treating these mice with an eTau-neutralizing antibody (IPN002)
reduced endogenous murine Ab in both their ISF and brain. Finally,
in vitro we demonstrate that eTau treatment increases neuronal
hyperactivity. We propose that this eTau driven neuronal hyper-
activity increase, results not only in increased Ab secretion but also
in a further increase in eTau secretion, and that together eTau and
Ab create a feed forward disease mechanism that perpetuates the
disease (Supplementary Fig. 4).
We examined the conditioned media of AD patientederived
cortical neurons for the presence of tau in the absence of neuronal
lysis and found tau fragments. Analysis of the tau fragments by LC/
MS for primary sequence and posttranslational modiﬁcations
showed that this secreted tau is composed predominantly of 4 N-
terminal fragments, all containing an N-terminal acetylated alanine
and a low percentage (<5%) canonical tau phosphorylations (at
p181, p202, and p231 using 2N4R designation). Immunoprecipita-
tion and LC/MS analysis showed minimal evidence of full-length
tau and no C-terminal tau fragments, suggesting that tau is pro-
cessed to eTau in the cytoplasm before secretion. Future efforts
could determine how and why tau is processed to these N-terminal
fragments and may also help clarify the mechanism by which eTau
is secreted from neurons.
The size of the identiﬁed eTau species varies from 171 amino
acids for eTau1 (aa 2e44, 103e230) to 67 amino acids for eTau4 (aa
2e44,103e126). Themolecular weight and immunoreactivity of the
isolated eTau species is similar to that of the tau fragments found in
the CSF of AD and control patients (Meredith et al., 2013; iPierian,
data not shown). We furthermore show that tau in the ISF of P301L
mice is also truncated. Our data, together with Meredith et al.
(2013), suggest that the eTau secreted from patient-derived
cortical neurons is physiologically relevant and is representative
of the tau secreted into the CSF of AD patients in disease. This is in
contrast to Yamada et al. (2011) which shows an immunoreactive
band at 50 kd, suggestive of full-length tau, present in the ISF of
P301L mice. The reason for these differences remains to be deter-
mined. Our results show for the ﬁrst time that endogenously
generated and secreted tau from AD patient neurons can been
puriﬁed and characterized, making it now possible to study eTau’s
potential role in the accumulation of Ab and tau pathology.
Using the puriﬁed eTau from conditioned media, we identiﬁed
high afﬁnity tau antibodies capable of recognizing all 4 eTau frag-
ments. Some of these antibodies speciﬁcally neutralized eTau’s ef-
fects; capable both of lowering Ab production and of blocking eTau
induced neuronal hyperexcitability. IPN002 is our strongest eTau
neutralizing antibody.
To investigate the mechanism by which eTau may regulate Ab
levels we looked at the proteolysis of APP. Treating neurons with
either puriﬁed endogenous eTau or synthetic eTau both increased
Ab levels, where treatment with eTau binding antibodies decreased
Ab levels. The mechanism by which a- and b-secretase compete for
Fig. 7. Secreted tau and Ab production are driven by neuronal excitability state. Human secreted tau induces neuronal hyperactivity. Primary human neuron cultures treated with
TTX for Ab and total tau ELISA endpoints; TTX present for 20 days in total; conditioned media harvested and cells retreated every 5 days. (A) In a dose and time-dependent manner,
TTX treatment lowers Ab40 levels up to 20% (7778  92 pg/mLe6203  443 pg/mL) and Ab42 levels up to 25% (1316  29 pg/mLe985  108 pg/mL). Error bars are STD on mean pg/
ml Ab levels. One-way ANOVA with Tukey correction; Ab40, day 15 and 20, Basal versus 100 nM TTX *p < 0.0001; Ab42, day 15, Basal versus 30 nM TTX *p ¼ 0.0109; day 15, Basal
versus 100 nM TTX yp ¼ 0.0001; day 20, Basal versus 30 nM TTX zp ¼ 0.0001; day 20, Basal versus 100 nM TTX xp < 0.0001. (B) TTX treatment signiﬁcantly lowers secreted eTau
levels up to 60% by day 15 with 100 nM TTX (0.373  0.07 AUe0.14823  0.026 AU). Error bars are STD on mean tau ELISA units; 1-way ANOVAwith Tukey correction day 10 and day
15, Basal versus 30 nM and 100 nM TTX *p < 0.0001. Electrophysiology experiments done on both primary human cortical neuron cultures and iPSC derived cortical neuron cultures.
(C) Current clamp recordings show that puff application of puriﬁed eTau, but not full length tau (3 mM rTau383), increases neuronal activity in both iPSC-CN (100 nM, upper panels)
and in primary human cortical neuron cultures (300 nM, lower panel). (D) Bath application of puriﬁed eTau (50 nM) onto primary human cortical neuron cultures increases neuronal
activity which is reduced by the addition of the anti-tau antibody, IPN002 (500 nM). Bar graph shows mean % reduction of eTau induced hyperactivity in primary human neurons
when IPN002 is added to cultures, values are background normalized and averaged over 4 experiments. Abbreviations: Ab, amyloid-beta; ANOVA, analysis of variance; ELISA,
enzyme-linked immunosorbent assay; eTau, extracellular tau; iPSC, induced pluripotent stem cells; STD, standard deviation; TTX, tetrodotoxin.
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APP processing is mitigated if a-secretase cleaves APP before
b-secretase; a-secretase clips in the middle of the Ab region
releasing a soluble APP fragment, sAPPa leaving a short C-terminal
cellular fragment. We found that eTau treatment of human cortical
cultures results in a simultaneous increase in Ab and a decrease in
sAPPa, leading us to conclude that eTau affects the cleavage of APP.
Our experiments showing the concurrent decrease in sAPPa levels
with the increase in Ab40-Ab42 levels support the idea that a- or
b-secretase cleavage of APP is coupled.
When we reduced tau protein levels with MAPT siRNA or
neutralized eTau with MC1 and IPN002 tau antibodies, levels of
sAPPa always moved in the opposite direction to Ab40-Ab42 levels.
Analysis of the cell lysates of treated neurons by APP Western blot
also indicate that neutralizing eTau favors the formation of the
C-terminal cellular fragment cleavage fragment of APP over the
b-secretase generated b-CTF.
Importantly, we were able to show that only the tau antibodies
capable of binding eTau could affect Ab production. The tau anti-
body PHF1, which does not bind to eTau, does not reduce Ab levels,
conﬁrming that it is secreted eTau that is affecting APP proteolysis
and Ab levels and not full-length tau.
Our in vivo studies using human tau transgenic mice support the
idea that eTau affects Ab levels. The data from our 26-week tau-4R/
2N-P301L van Leuven transgenic tau animal study show endoge-
nousmurine Ab increases with age. This elevationwas not observed
in nontransgenic mice, suggesting that the observed increase in
mouse Ab in the older P301L mouse is driven by continued human
tau expression. Dosing 2 strains of P301L tau transgenic mice, in 2
distinct studies with the eTau binding antibody, IPN002, signiﬁ-
cantly decreased endogenous murine Ab levels.
Our studies, in vitro and in vivo, show that reducing or
neutralizing eTau lowers Ab production. This ﬁnding is in contrast
to the in vivo hAPP mouse studies by Roberson et al. (2007) and
Ittner et al. (2010). These hAPP studies demonstrate that dose-
dependent reductions of mouse tau protect mice from hAPP
driven neuronal dysfunction; however, eliminating mouse tau in
these studies did not affect the levels or aggregation of transgenic
Ab. One possible explanation for this divergence in ﬁndings is that
human tau but not mouse tau is capable of regulating Ab levels. The
ﬁndings in Ribe et al. (2005) that human tau overexpression in-
creases the Ab burden in a human APP and tau bigenic mouse
model when compared with single transgenic control animals
supports this claim.
We were able to conﬁrm this putative activity difference in
mouse and human tau by treating our primary human cortical
cultures with human eTau 4 (aa 2e44,103e126) or the equivalent
amino acid sequence frommouse tau. Synthetic human eTau 4, but
not the equivalent mouse tau peptide, increased Ab levels. Because
these peptides were synthetically generated, the only difference
between mouse and human eTau 4 treatments is the variation in
their primary sequence. We were further able to show that a pep-
tide composed only of the human tau insert region, the sequence
absent from mouse tau, was able to increase Ab production on its
own. Thus, it appears that the human tau insert region at the N-
terminus of tau regulates Ab production and explains the human
speciﬁcity of this observation.
Finding that N-terminally truncated tau regulates Ab levels
where full-length tau cannot suggest that a change in the secondary
structure of the truncated fragments versus full-length tau confers
an activity difference. Full-length tau protein in solution has been
described alternatively as unordered (Schweers et al., 1994) and in
other studies as having a “paperclip” conformation, where the
amino- and carboxyl-terminal domains are folded back on each
other (Jeganathan et al., 2006). In either case, our ﬁndings suggestthat removing the C-terminus of the protein may change the sec-
ondary structure of tau, exposing the putative “active region” of
eTau, the human tau insert region (aa 17e28), which being exposed
can then affect Ab levels.
In light of the observations that Ab production is regulated by
neuronal activity (Kamenetz et al., 2003) as well as observations
implicating tau in the regulation of excitability and synchronization
of neuronal networks (Holth et al., 2013), we asked if eTau could
affect neuronal hyperactivity. We found that treatment of primary
cortical neurons with eTau but not full-length tau increases
neuronal hyperactivity and that neuronal hyperactivity caused
further secretion of eTau. Additionally, we showed that reducing or
neutralizing eTau lowers the production of Ab40 and Ab42 and
prevents eTau-dependent neuronal hyperactivity. We therefore
suggest that eTau induced neuronal hyperactivity may be the
mechanism by which eTau is affecting Ab production in the brain.
Interestingly, it takes between 10 and 20 days for eTau to increase
Ab production, whereas eTau induces hyperactivity within seconds.
This suggests that an adaptive process that is neuronal hyperac-
tivity dependent may be responsible for this time lag in regulating
Ab production.
Finally, the amount of exogenous eTau needed to elicit neuronal
hyperactivity as well as to affect Ab and sAPPa levels is higher
than the circulating levels of tau found in AD patient CSF or in
the conditioned media of our primary cortical cultures and
iPSC-cortical neurons. However, it has been proposed that activity-
dependent secretion of tau may occur through synaptic trans-
mission (Braak et al., 2013; Liu et al., 2012; Yamada et al., 2014).
Therefore, eTau secretion through a synaptic mechanism would
necessarily generate local eTau concentrations at the release site,
and likely site of action, which are signiﬁcantly higher than circu-
lating levels of eTau.
The exact nature of the relationship between Ab and tau, the 2
hallmark proteins involved in the pathology of AD has long been
unclear. The amyloid hypothesis suggests that Ab is the primary
driver in AD. Patients with Down syndromewho carry an extra copy
the APP gene or express hereditary APP mutations all suffer from
earlier onset of dementia and a more severe disease pathology.
Alternatively to the amyloid cascade idea, Braak and Schonheit
work with human autopsy material has clearly found that Ab de-
posits are seen later than intraneuronal tau changes in subregions
of the AD brain (Braak and Del, 2004; Braak et al., 2013; Schonheit
et al., 2004). Additionally, Ribe et al. (2005) using an APP/tau double
transgenic mouse model have shown that human tau over-
expression increases the Ab burden over single transgenic animal
controls, indicating that human tau is capable of modulating Ab
production or deposition.
Our studies, both in vitro and in vivo, indicate that tau plays a
role in regulating Ab production, an activity conferred by secreted
N-terminal fragments of tau and not full-length tau. We propose
that eTau is modulating Ab levels through its induction of neuronal
hyperactivity. In agreement with the observation that even partial
reductions in soluble Ab levels can have a profound impact on the
development of Ab pathology (McConlogue et al., 2007), our data
identifying secreted eTau fragments and their effect on Ab pro-
duction are an important step forward to understanding the rela-
tionship of tau and Ab in the progression of AD.
Our results taken together with previous ﬁndings align the 2
main players in AD, placing tau and Ab in a disease-perpetuating
loop as depicted in the diagram (Supplementary Fig. 4). The ﬁeld
has shown that tau mediates Ab induced neuronal dysfunction, and
we now show that secreted eTau modulates the process of APP
cleavage, changing the putative balance between the neuro-
protective sAPPa and amyloidogenic Ab40-Ab42 in a neuronal ac-
tivity state dependent manner. In addition to strengthening the
J. Bright et al. / Neurobiology of Aging 36 (2015) 693e709708connection between tau and Ab, these ﬁndings underscore the
potential utility in neutralizing eTau in the clinical setting of AD
with therapeutics such as humanized versions of the IPN002 tau
antibody. Neutralizing eTau in patients can potentially inhibit the
spread of tau and tau pathology in the brain, reduce CNS Ab levels
and subsequent neuronal hyperactivity, and potentially slow the
clinical progression into dementia. This strategy may offer the ﬁrst
of its kind dual therapy for this debilitating disease.
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